Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Caixa Seguridade Participacoes SA
BOVESPA:CXSE3
|
BR |
Genfit SA
Total Current Assets
Genfit SA
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Assets
€155.4m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
8%
|
|
|
Valneva SE
PAR:VLA
|
Total Current Assets
€268.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
9%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Assets
€172.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Current Assets
$121.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
1%
|
|
|
Abivax SA
PAR:ABVX
|
Total Current Assets
€86m
|
CAGR 3-Years
25%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Current Assets
€97.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Total Current Assets?
Total Current Assets
155.4m
EUR
Based on the financial report for Jun 30, 2025, Genfit SA's Total Current Assets amounts to 155.4m EUR.
What is Genfit SA's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
8%
Over the last year, the Total Current Assets growth was 14%. The average annual Total Current Assets growth rates for Genfit SA have been -11% over the past three years , -8% over the past five years , and 8% over the past ten years .
